How we support drug discovery research
At Cancer Research UK (CRUK) we have a strong track record of therapeutic discovery. And thanks to our extensive portfolio of basic research and our strengths in drug development, we ensure that innovation in cancer treatment benefits patients sooner.
Our new funding opportunity, the Therapeutic Catalyst, will accelerate the translation of laboratory discoveries into novel cancer therapeutics in collaboration with CRUK drug discoverers. The partnership will utilise the expertise of both the researcher and CRUK drug discoverers to accelerate early therapeutic opportunities. We strongly encourage researchers with novel insights into cancer biology that can be targeted therapeutically to treat cancer to apply for this new opportunity.
Our Therapeutic Discovery awards, including the Therapeutic Discovery Pilot Award, the Therapeutic Discovery Project Award, and the Therapeutic Discovery Programme Award are currently on pause.
We’re in the process of reviewing our therapeutic offering. We will provide an update as soon as we can by early 2022.
We have also made extensive investment in the infrastructure of drug discovery, and our specialist laboratories are available to support CRUK researchers.
The CRUK–AstraZeneca Antibody Alliance Laboratory is accelerating the translation of cancer research into potential new biotherapeutic drugs. This innovative collaboration with AstraZeneca's global biologics research and development arm enables CRUK researchers to access AstraZeneca's capabilities and technology.
Cancer Research UK Drug Discovery Units
Our core-funded Drug Discovery Units have an extensive experience and diverse expertise in small molecule drug discovery. CRUK researchers seeking to translate their research are encouraged to build collaborations with appropriate drug discovery groups.
Our Therapeutic Discovery Laboratories (TDL) in London and Cambridge bring the best minds in basic and clinical cancer research together with the rigour and drive of pharmaceutical and biotech companies.
Our alliance engages with academic researchers to accelerate the translation of discovery science to new immunotherapies. If you're a researcher working in the immuno-oncology space and have identified a potential target or a platform technology for target identification, we'd love to hear from you.